About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 379 record(s)
Req # A-2023-000787
Adverse Drug Reaction (ADR) for CHLORHEXIDINE. Report number: 001036984.Organization: Health Canada
September 2023
Req # A-2022-00007
All emails and other records that were received/or sent between June 8, 2022 and August 12, 2022 by either the President (Lisa Campbell), Science Advisor (Sarah Gallagher), Chief of Staff (Nathalie Verville) or Vice President of Science and Technology (Luc Brûlé or Luc Brule) that include any reference to either "Spergel", "UAP", "unidentified aerial phenomena''. "unidentified aerial phenomenon", "UFO", "unidentified flying object" or "Galileo Project".Organization: Canadian Space Agency
September 2022
Req # A-2022-00008
Please provide a copy of the final funding agreement between the department and the proponents of the project detailed here: https://search.open.canada.ca/grants/record/csa-asc,003-2021-2022-Q3-00031,currentOrganization: Canadian Space Agency
September 2022
Req # A-2019-001009
Adverse Drug Reactions (ADRs) for Chlorhexidine. Report numbers: 000725334, 000725411, 000725428, 000725434, 000725439, 000725442, 000725446, 000725500, 000725506, E2B_02466826, E2B_02467708, E2B_02467710, E2B_02469532, E2B_02479840, 000725624, 000725643, 000725711, 000725770, 000725821, 000725822, 000725824, E2B_02535786. ADRs for Nicotine. Report numbers: 000723298, E2B_02446830, E2B_02456263, E2B_02478261, E2B_02478354, E2B_02487552, E2B_02491357,E2B_02494777, E2B_02508747, E2B_02532088.Organization: Health Canada
September 2022
Req # A-2019-001729
Adverse Drug Reactions (ADRs) for immunoglobulin (human). Report numbers: 000729698, 000729737, 000729753, E2B_02721074, E2B_02725284, E2B_02745409, E2B_02745430, E2B_02757454, E2B_02757460, E2B_02757483, E2B_02758498, E2B_02758510, E2B_02761164, E2B_02761166, E2B_02762212, E2B_02770935, E2B_02790551, E2B_02790674, E2B_02791333, E2B_02806975.Organization: Health Canada
September 2022
Req # A-2020-000935
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-109891-294.Organization: Health Canada
September 2022
Req # A-2020-001118
Adverse Drug Reactions (ADRs). Report numbers: E2B_02194141, E2B_02194231, E2B_02196619, E2B_02196705, E2B_02196717, E2B_02199201, E2B_02199223, E2B_02199231, E2B_02199293, E2B_02199808, E2B_02200059, E2B_02201762, E2B_02202036, E2B_02202050, E2B_02202243, E2B_02202438, E2B_02202454, E2B_02202528, E2B_02203600, E2B_02204012.Organization: Health Canada
September 2022
Req # A-2020-001145
Adverse Drug Reactions (ADRs). Report numbers: E2B_02321406, E2B_02321840, E2B_02323070, E2B_02323093, E2B_02323110, E2B_02323596, E2B_02323621, E2B_02324669, E2B_02325522, E2B_02326954, E2B_02326990, E2B_02327172, E2B_02328369, E2B_02328379, E2B_02328380, E2B_02328405, E2B_02328424, E2B_02328614, E2B_02329080, E2B_02329268.Organization: Health Canada
September 2022
Req # A-2020-001184
Adverse Drug Reactions (ADRs). Report numbers: E2B_02424240, E2B_02424378, E2B_02424435, E2B_02424630, E2B_02425161, E2B_02425170, E2B_02425179, E2B_02427052, E2B_02427055, E2B_02427212, E2B_02427224, E2B_02427228, E2B_02427229, E2B_02427233, E2B_2427312, E2B_02427435, E2B_02428405, E2B_02428423, E2B_02428753, E2B_02429833.Organization: Health Canada
September 2022
Req # A-2020-001345
Adverse Drug Reactions (ADRs). Report numbers: E2B_02079242, E2B_02086576, E2B_02087040, E2B_02207354, E2B_02218589, E2B_02247236, E2B_02251088, E2B_02271649, E2B_02274332, E2B_02285866, E2B_02290975, E2B_02297390, E2B_02297391.Organization: Health Canada
September 2022